Clinical considerations related to hydrocodone rescheduling

The following letter was sent to members of the American Academy of Pain Management on September 3, 2014.  The Academy is posting this as an open letter in an effort to prepare clinicians for the upcoming rescheduling of hydrocodone-containing combination products so that they may continue to provide optimal pain management to their patients. ~ […]

Changes coming for some pain medicines

On August 22, 2014, the US Drug Enforcement Administration (DEA) made a rule that puts new controls on some kinds of pain medicine. This rule comes after lots of government agencies and groups for people with pain, people with drug abuse problems, and healthcare providers have discussed it for more than 10 years. The DEA’s […]

Pain treatments less effective for those with irritable bowel

The immune system is defective in those suffering from irritable bowel syndrome (IBS).  This, according to new research out of the University of Adelaide, may explain why some pain relievers may not offer adequate relief to those with IBS.  Lead author Dr. Patrick Hughes says, “The gut contains specialised immune cells, known as monocytes and […]

Hydrocodone combination products to be rescheduled on October 6, 2014

After many months of hearings, public comments, and a turnaround decision by the FDA to recommend up-scheduling, a final rule was published in the Federal Register today that will move hydrocodone combination products (HCP) from their previous spot in Schedule III under the federal Controlled Substances Act to the more restrictive Schedule II.  The rule […]

Pain assessment very difficult in deaf patients

There should be an American Sign Language (ASL) interpreter present at every encounter between a deaf pain patient and his or her healthcare providers, according to the results of a series of focus groups.  There are many barriers to effectively assessing a deaf patient for pain.  Including the obvious communications barriers, there is a lack […]